AzTrials
AzTrials

RV - Right Ventricular AbnormalityNCT06739057

Pediatric Ventricle Function Assessment Study

An observational study of RV - Right Ventricular Abnormality and LV Dysfunction, run by HBI Solutions Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction. Read more about this study

Who is it for?
Ages Up to 18 yearsHealthy volunteers can take part
How many people
3,993 participants
Where
1 siteUnited States
Study dates
1 Jan 2014to 31 Aug 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: Two groups of children are included. Group I: Children with normal right ventricular anatomy and function assessment based on screening echocardiograms and physcian follow up. Group II: Children with right ventricular abnormalities who have potential risk of adverse outcomes.

Who may be able to join

  • Patients aged 0-18 years old.
  • Patients with the following diagnoses (defined as abnormal RVs): premature infants with lung disease, congenital heart disease with systemic right ventricles, surgically repaired congenital heart disease resulting in pressure and/or volume load on the RV (tetralogy of Fallot, Double outlet right ventricle, etc.), and idiopathic pulmonary hypertension.

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Stanford University

    Palo Alto, California, 94304

Other trials in United States

About this study

This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction. The AI model was designed to distinguish between normal pediatric hearts, pulmonary hypertension (PH), and Tetralogy of Fallot (TOF). To improve diagnostic accuracy, the investigators extended the analysis beyond the A4C view by integrating data from both A4C and PSAX views. Additionally, the framework was applied to predict left ventricular ejection fraction (LV EF), further showcasing its versatility and clinical utility.

Read the detailed description

Heart defects are a leading cause of birth defect-associated illness and mortality worldwide, affecting approximately 1% of live births globally. Among these, about one-quarter1 present with critical heart defects requiring early intervention to improve survival and outcomes.Right ventricular (RV) dysfunction is a prevalent form of heart disease in pediatric patients, often arising from conditions such as prematurity, post-surgical effects of congenital heart disease, functioning as the systemic ventricle, and idiopathic pulmonary hypertension. These patients face significant risks, including RV failure, decreased quality of life, potential need for transplantation, and increased mortality. Accurate assessment of RV function is crucial but challenging due to the RV's complex geometry.

Unlike left ventricular (LV) dysfunction, RV dysfunction primarily results from pressure and volume overloads and has unique pathophysiological characteristics. While LV dysfunction mechanisms are well-studied, less is known about RV, and much of its clinical management is adapted from LV-focused research. The RV, with its thinner and more adaptable walls, remodels efficiently but often tolerate changes for extended periods before failure. Furthermore, RV dysfunction frequently leads to LV dysfunction due to strong interventricular interactions. These differences, along with the RV's irregular shape and orientation, complicate imaging and assessment, requiring advanced imaging techniques, often involving multiple modalities.

Precise evaluation of RV size and function is essential for diagnosing, managing, and predicting outcomes in pediatric cardiac conditions. Echocardiography, as a non-invasive and accessible tool, is the first-line imaging technique for monitoring RV function). However, traditional RV functional measures face limitations in pediatric populations due to significant variability in RV morphology. Among systolic parameters, fractional area change (FAC) has demonstrated stronger correlations with disease severity in advanced heart failure patients and a closer relationship with RV ejection fraction as measured by cardiovascular magnetic resonance (CMR), suggesting its reliability in assessing pediatric RV function. An FAC <35% is considered abnormal by the guideline. Accurate FAC assessment can guide timely interventions, improve prognosis, and enhance long-term outcomes by enabling better monitoring of RV function over time.

Congenital Heart Disease (CHD) includes a wide range of structural abnormalities and conditions that affect the heart's development before birth, with examples such as Tetralogy of Fallot (TOF) and Pulmonary hypertension(PH). The RV plays a crucial role in TOF diagnosis because its outflow tract obstruction and hypertrophy are primary features of the condition. Pulmonary hypertension increases the afterload (pressure) on the right ventricle, leading to RV structural and functional changes. These changes are typically not seen in the LV unless there is severe biventricular involvement or secondary effects.

Echocardiography is a non-invasive, widely accessible, and essential first-line tool for routine follow-up of various pediatric cardiac conditions affecting the right ventricle (RV). However, assessing RV function in pediatric heart disease remains challenging due to significant variability in RV morphology and physiology. The apical four-chamber (A4C) view is a cornerstone for right ventricular (RV) function assessment due to its ability to evaluate RV size, shape, and systolic function comprehensively. The parasternal short-axis (PSAX) view is often used as a supplementary echocardiographic view alongside the A4C view for assessing right ventricular (RV) function. Advances in AI-driven echocardiography, particularly deep learning, hold promise for enhancing cardiac function assessment. Recent innovations, like EchoNet-Dynamic, have shown the utility of video-based deep learning algorithms for adult LV segmentation and ejection fraction estimation. Building on this progress, the investigators developed EchoNet-Peds , an AI model for pediatric echocardiography that automates LV segmentation and ejection fraction calculations. Beside left ventricle segmentation methods, other deep learning applications include automated quantification of left ventricular structure and function, as well as novel methods for estimating intraventricular hemodynamic parameters on a beat-to-beat basis . However, most deep learning studies focus on LV assessment, with comparatively fewer models dedicated to the RV, mainly addressing segmentation tasks. While some recent advancements have emerged, such as a model estimating RV ejection fraction from echocardiographic images in pulmonary arterial hypertension patients , significant gaps remain in applying AI to pediatric RV functional assessment.

This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction. The AI model was designed to distinguish between normal pediatric hearts, pulmonary hypertension (PH), and Tetralogy of Fallot (TOF). To improve diagnostic accuracy, the investigators extended the analysis beyond the A4C view by integrating data from both A4C and PSAX views. Additionally, the framework was applied to predict left ventricular ejection fraction (LV EF), further showcasing its versatility and clinical utility.

Keywords
Echocardiogram, Right Ventricle (RV), Pulmonary Hypertension, TOF
Medical subject headings
Ventricular Dysfunction, Left, Hypertension, Pulmonary

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06739057
Study groupRoleWhat they receive
RV FAC Prediction CohortThis cohort is designed to predict pediatric RV FAC using a deep learning model based on echocardiograms
RV Disease Classification CohortThe cohort is designed to employ a deep learning model to differentiate between normal pediatric hearts and pulmonary hypertension (PH), as well as between Tetralogy of Fallot (TOF) and PH, using echocardiograms.
RV Function Assessment and Disease Classification Using A4C and PSAX View CohortsThe cohort is designed to utilize A4C and PSAX echocardiographic views for pediatric RV function assessment and disease classification using deep learning models.
LV Ejection Fraction (EF) Prediction CohortThe cohort is designed to validate our new deep learning model for LV EF assessment.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. RV dysfunction prediction

    FAC < 35% is considered RV abnormal. The automated extracted FAC values were then used to predict the probability of abnormal RV function.FAC estimation accuracy was evaluated using mean absolute error (MAE), root mean squared error (RMSE), and Pearson correlation coefficient (R). Diagnostic performance metrics included AUC, sensitivity, and specificity for RV function assessment

    Measured: 10 minutes

  2. Congenital Heart Disease Detection

    For CHD detection, classification models were developed to distinguish between normal, PH, and TOF cases by analyzing RV echocardiogram videos. Accuracy, sensitivity, and specificity were used to evaluate the classifications of PH versus normal and PH versus TOF

    Measured: 10 minutes

  3. Left Ventricle Dysfunction

    The performance is assessed by calculating the area under the receiver operating characteristic (ROC) curve , evaluating the model's accuracy in detecting abnormal EF values.

    Measured: 10 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Dec 2024
  2. Study start1 Jan 2014
  3. Primary completion31 Aug 2024
  4. Study completion31 Aug 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
3,993 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06739057
Sponsor's protocol ID
ECHO_1
Status last verified
Dec 2024
First submitted
12 Dec 2024
Last updated
20 Dec 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of RV - Right Ventricular Abnormality and LV Dysfunction, run by HBI Solutions Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

RV dysfunction prediction (time frame: 10 minutes). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in